CRGX: רווח נקי למניה (EPS TTM) Cargo Therapeutics

לוגו של חברה ציבורית CARGO Therapeutics Inc. (CRGX)

The intensive R&D phase for developing next-generation CAR-T therapy has triggered a sharp impulse in the 12-month rolling EPS for CARGO Therapeutics (CRGX). Diversifying targets against lymphomas mitigates risks, yet geopolitical isolation and the disruption of biomaterial logistics are hindering research. The current level of -4.67 captures the current value of the indicator, determining the business's financial resilience to Fed rates.

CRGX (CARGO Therapeutics) היסטוריית רווח נקי למניה אחת בשנים עשר החודשים האחרונים מ-21.02.2024 עד 30.08.2025

CARGO Therapeutics - פילוחים אנליטיים ומדדי מפתח (CRGX)

ניתוח כללי של החברה:cargo-tx.com (CRGX)
מוצר סדרתי של CARGO Therapeutics, Inc

Net income per share over 12 months determines the portion of profit attributable to a single security, accounting for all capital adjustments. The 12-month net income per share trend on the GURU.Markets platform reflects the efficiency of resource allocation. The calculation is based on dividing the total annual net income by the weighted average number of shares. For CARGO Therapeutics (CRGX), this indicator verifies the targeted utilization of R&D budgets. Management's expertise in cancer therapy enables the optimization of expenses, minimizing the risks of declining investment attractiveness.

ניתוח חברות מתחרות